Traumatic Brain Injuries Treatment Market Research Report - Forecast till 2027

Traumatic Brain Injuries (TBI) Treatment Market Research Report: by treatment (immediate emergency care, medications (diuretics, analgesic and others), surgery), end-users (hospitals, neurologist, independent pharmacies and others) -Forecast till 2027

ID: MRFR/Pharma/5374-HCR | February 2021 | Region: Global | 90 pages

Traumatic Brain Injuries (TBI) Treatment Market Scenario:


Traumatic brain injuries treatment market is expected to rise steadily at a CAGR of 5.1% during forecast period of 20182023.


Traumatic brain injuries treatment (TBI) is an interruption in the normal function of the brain. It is a serious public health problem and is the leading cause of brain injury with at least 1.7 million people sustaining such injury every year. Traumatic brain injuries contribute to a substantial number of death and permanent disability every year. About 52,000 people dies of this injury which are commonly caused by car accident, falls, blunts force trauma, violent assaults and sporting injuries. An estimated 2.8 million people suffers from traumatic brain injuries treatment annually in United States of which 50,000 dies and 282,000 are hospitalized. Every day 153 people in United States die from TBI injury. 


Numerous factors propelling the growth of this market are rising number of road traffic collisions and increasing number of aging populations. Whereas growing interests in research activities on diagnosis of TBI and new pipeline of drugs are further boosting the growth of traumatic brain injuries treatment market.


Despite the drivers, factors such as high cost of treatment and the use of monitoring devices may hinder the growth of market.


Segmentation:


Traumatic brain injuries treatment market is further segmented into treatment types and end-users.


Based on treatment types the market is segmented into immediate emergency care, medications and surgery. On basis of medication global traumatic brain injuries treatment market is further sub-segmented into diuretics, anti-seizure drugs, coma-inducing drugs, anti-anxiety agent, anti-depressants, anti-psychotics, analgesic, anti-convulsant and anti-coagulants. Based on surgery, TBI market is further sub-segmented into removing clotted blood (hematomas), repairing skull fractures, bleeding in the brain, opening a window in the skull, rehabilitation.


On basis of end-users global traumatic brain injuries treatment market is further segmented into hospitals, neurologist, rehabilitative centre treatment, independent pharmacies and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The traumatic brain injuries treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injuries treatment market.  


The European traumatic brain injuries treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The traumatic brain injuries treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The traumatic brain injuries treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players:


Some of the key players in the global traumatic brain injuries treatment market are Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc, TEVA Pharmaceutical Industries Ltd, Ischemic, Grace Laboratories LLC. Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, NeuroScience Pharmaceuticals, Targacept. BioDirection, Inc., QuesGen Systems, Inc., BrainScope Company, Inc., Neural Analytics, Inc, Oculogica, BrainScope Company, Inc, Silver Creek, Pharmaceuticals Inc, Stemedica Cell Technologies Inc, Banayan Biomarkers Inc, Vasopharm GmbH, Zimmer Biomet.


Regional Market Summary
Global Traumatic Brain Injuries Treatment Market Share (%), by Region, 2017


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon


Geographically, the Americas is anticipated to dominate the global traumatic brain injuries treatment market. The market growth in this region is attributed to the increasing incidences of road accident in this region. Moreover, increasing investment by government in research and development of drug pipeline in treatment of TBI has boosted the market growth in this region. According to the Health United States Report 2016, 2.8 million people sustains TBI annually of which 50,000 dies and 282,000 are hospitalized and about 2.5 million nearly 90% are treated and released from emergency department. TBI contributes to 30% injury related death in United States. 


Europe is expected to be the second largest market in the globe owing to the increasing aging population and increasing prevalence of TBI in low- and middle-income countries. According to the data collected by journal of neurosurgery the overall incidence of TBI per 100,000 people was highest in Europe and about 95% of population suffered from TBI injury due to increasing incidences of road traffic collisions.


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of road traffic collision in the developing countries. Whereas Southeast Asian and Western Pacific region experiences the highest burden of TBI disease.


The proportion of TBI resulting from road traffic collision was found greatest in Africa and Southeast Asia.


Traumatic brain injuries treatment Market, by Treatment



  • Immediate emergency care

  • Medications

    • Diuretics

    • Anti-seizure drugs

    • Coma-inducing drugs

    • Anti-anxiety agent

    • Anti-depressants

    • Anti-psychotics

    • Analgesic

    • Anti-convulsant

    • Anti-coagulants



  • Surgery

    • Removing clotted blood (hematomas)

    • Repairing skull fractures

    • Bleeding in the brain

    • Opening a window in the skull

    • Rehabilitation




Traumatic brain injuries treatment Market, by End User



  • Hospitals

  • Neurologist

  • Independent pharmacies

  • Rehabilitative centre treatment

  • Other


Traumatic brain injuries treatment Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific



  • Middle East & Africa

    • Middle East

    • Africa




Traumatic brain injuries treatment Market, by Key Players



  • Zimmer Biomet

  • Neuren Pharmaceuticals Ltd.

  • Oxygen Biotherapeutics Inc

  • TEVA Pharmaceutical Industries Ltd

  • Ischemic

  • Grace Laboratories LLC

  • Cognosci

  • Medicortex

  • Amarantus BioScience Holdings

  • Aldagen

  • NeuroScience Pharmaceuticals

  • Targacept

  • BioDirection, Inc.

  • QuesGen Systems, Inc.

  • BrainScope Company, Inc.

  • Neural Analytics, Inc

  • Oculogica

  • BrainScope Company, Inc

  • Silver Creek Pharmaceuticals Inc

  • Stemedica Cell Technologies Inc

  • Banayan Biomarkers Inc

  • Vasopharm GmbH


Intended Audience



  • Manufacturers and Suppliers

  • Neurologist hospitals and clinics

  • Laboratories and Associations



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.1% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment Types and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Neuren Pharmaceuticals Ltd., Oxygen Biotherapeutics Inc, TEVA Pharmaceutical Industries Ltd, Ischemic, Grace Laboratories LLC. Cognosci, Medicortex, Amarantus BioScience Holdings, Aldagen, NeuroScience Pharmaceuticals, Targacept. BioDirection, Inc., QuesGen Systems, Inc., BrainScope Company, Inc., Neural Analytics, Inc, Oculogica, BrainScope Company, Inc, Silver Creek, Pharmaceuticals Inc, Stemedica Cell Technologies Inc, Banayan Biomarkers Inc, Vasopharm GmbH, Zimmer Biomet
  Key Market Opportunities

  • Growing interests in research activities on diagnosis of TBI
  • New pipeline of drugs
  •   Key Market Drivers

  • Rising number of road traffic collisions
  • Increasing number of aging populations


  • Frequently Asked Questions (FAQ) :


    Traumatic Brain Injuries Treatment (TBI) Market would record a 5.1% CAGR during the forecast period of 2020-2027.

    High treatment cost and inclusion of monitoring devices can impact the growth of the Traumatic Brain Injuries Treatment (TBI) Market.

    Traumatic brain injuries treatment would be driven by the Americas.

    US would lead the American Traumatic Brain Injuries Treatment (TBI) Market.

    Asia Pacific would be the fastest-growing Traumatic Brain Injuries Treatment (TBI) Market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Traumatic Brain Injury Treatment Market , by Treatment

    6.1 Introduction

    6.2 Immediate emergency care

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Medications

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.1 Diuretics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.2 Anti-seizure drugs

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.3 Coma-inducing drugs

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.4 Anti-Anxiety Agent

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.5 Anti-Depressants

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.6 Anti-Psychotics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.7 Analgesic

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.8 Anti-Convulsants,

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.9 Anti-Coagulants

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Surgery

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4.1 Removing clotted blood (hematomas)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4.2 Repairing skull fractures

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4.3 Bleeding in the brain

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4.5 Opening a window in the skull

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4.6 Rehabilitation

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Traumatic Brain Injury Treatment Market , by End-User

    7.1 Introduction

    7.2 Hospitals

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Neurologist

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Independent Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Rehabilitative Center Treatment

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.6 Other

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 8. Global Traumatic Brain Injury Treatment Market , by Region

    8.1 Introduction

    8.2 Americas

    8.2.1 North America

    8.2.1.1 US

    8.2.1.2 Canada

    8.2.2 South America

    8.3 Europe

    8.3.1 Western Europe

    8.3.1.1 Germany

    8.3.1.2 France

    8.3.1.3 Italy

    8.3.1.4 Spain

    8.3.1.5 UK

    8.3.1.6 Rest of Western Europe

    8.3.2 Eastern Europe

    8.4 Asia-Pacific

    8.4.1 Japan

    8.4.2 China

    8.4.3 India

    8.4.4 Australia

    8.4.5 South Korea

    8.4.6 Rest of Asia-Pacific

    8.5 Middle East & Africa

    8.5.1 Middle East

    8.5.2 Africa

    Chapter 9 Company Landscape


    9.1 Introduction

    9.2 Market Share Analysis

    9.3 Key Development & Strategies

    Chapter 10. Company Profiles

    10.1 Zimmer Biomet

    10.1.1 Company Overview

    10.1.2 Product Overview

    10.1.3 Financials Overview

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 Neuren Pharmaceuticals Ltd

    10.2.1 Company Overview

    10.2.2 Product Overview

    10.2.3 Financial Overview

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Oxygen Biotherapeutics Inc

    10.3.1 Company Overview

    10.3.2 Product Overview

    10.3.3 Financial Overview

    10.3.4 Key Development

    10.3.5 SWOT Analysis

    10.4 TEVA Pharmaceutical Industries Ltd

    10.4.1 Company Overview

    10.4.2 Product Overview

    10.4.3 Financial Overview

    10.4.4 Key Development

    10.4.5 SWOT Analysis

    10.5 Ischemic

    10.5.1 Company Overview

    10.5.2 Product Overview

    10.5.3 Financial overview

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 Grace Laboratories LLC

    10.6.1 Company Overview

    10.6.2 Product Overview

    10.6.3 Financial Overview

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 Cognosci

    10.7.1 Overview

    10.7.2 Product Overview

    10.7.3 Financial Overview

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Medicortex

    10.8.1 Overview

    10.8.2 Product Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.7 Amarantus BioScience Holdings

    10.7.1 Overview

    10.7.2 Product Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Aldagen

    10.8.1 Overview

    10.8.2 Product Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.11 NeuroScience Pharmaceuticals

    10.91 Overview

    10.92 Product Overview

    10.93 Financials

    10.94 Key Developments

    10.95 SWOT Analysis

    10.10 Targacept

    10.10.1 Overview

    10.10.2 Product Overview

    10.10.3 Financials

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.13 BioDirection, Inc

    10.13.1 Overview

    10.13.2 Product Overview

    10.13.3 Financials

    10.13.4 Key Developments

    10.13.5 SWOT Analysis

    10.14 QuesGen Systems, Inc

    10.14.1 Overview

    10.14.2 Product Overview

    10.14.3 Financials

    10.14.4 Key Developments

    10.14.5 SWOT Analysis

    10.15 BrainScope Company, Inc

    10.15.1 Overview

    10.15.2 Product Overview

    10.15.3 Financials

    10.15.4 Key Developments

    10.15.5 SWOT Analysis

    10.16 Neural Analytics, Inc

    10.16.1 Overview

    10.16.2 Product Overview

    10.16.3 Financials

    10.16.4 Key Developments

    10.16.5 SWOT Analysis

    10.17 Oculogica

    10.17.1 Overview

    10.17.2 Product Overview

    10.17.3 Financials

    10.17.4 Key Developments

    10.17.5 SWOT Analysis

    10.18 BrainScope Company, Inc

    10.18.1 Overview

    10.18.2 Product Overview

    10.18.3 Financials

    10.18.4 Key Developments

    10.18.5 SWOT Analysis

    10.19 Silver Creek Pharmaceuticals Inc

    10.19.1 Overview

    10.19.2 Product Overview

    10.19.3 Financials

    10.19.4 Key Developments

    10.19.5 SWOT Analysis

    10.20 Stemedica Cell Technologies Inc

    10.20.1 Overview

    10.20.2 Product Overview

    10.20.3 Financials

    10.20.4 Key Developments

    10.20.5 SWOT Analysis

    10.21 Banayan Biomarkers Inc

    10.21.1 Overview

    10.21.2 Product Overview

    10.21.3 Financials

    10.21.4 Key Developments

    10.21.5 SWOT Analysis

    10.22 Vasopharm GmbH

    10.22.1 Overview

    10.22.2 Product Overview

    10.22.3 Financials

    10.22.4 Key Developments

    10.22.5 SWOT Analysis

    Chapter 11 MRFR Conclusion

    11.1 Key Findings

    11.1.1 From CEO’s View point

    11.1.2 Unmet Needs of the Market

    11.2 Key Companies to Watch

    11.3 Predictions for the Traumatic Brain Injury Treatment Market

    Chapter 12. Appendix


    LIST OF TABLES

    Table 1 Global Traumatic Brain Injury Treatment Market Synopsis, 2020–2027

    Table 2 Global Traumatic Brain Injury Treatment Market Estimates and Forecast, 2020–2027

    (USD Million)

    Table 3 Global Traumatic Brain Injury Treatment Market , by Region, 2020–2027 (USD Million)

    Table 4 Global Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 5 Global Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)

    Table 6 North America: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 7 North America: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027

    (USD Million)

    Table 8 US: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 9 US: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)

    Table 10 Canada: Traumatic Brain Injury Treatment Market ,by Treatment , 2020–2027

    (USD Million)

    Table 11 Canada: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027

    (USD Million)

    Table 12 South America: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 13 South America: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)

    Table 14 Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027

    (USD Million)

    Table 15 Europe: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027

    (USD Million)

    Table 16 Western Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 17 Western Europe: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)

    Table 20 Eastern Europe: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027 (USD Million)

    Table 19 Eastern Europe: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)

    Table 20 Asia-Pacific: Traumatic Brain Injury Treatment Market , by Treatment , 2020–2027

    (USD Million)

    Table 21 Asia-Pacific: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027

    (USD Million)

    Table 22 Middle East & Africa: Traumatic Brain Injury Treatment Market , by Treatment, 2020-2027 (USD Million)

    Table 23 Middle East & Africa: Traumatic Brain Injury Treatment Market , by End-User, 2020–2027 (USD Million)




    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Traumatic Brain Injury Treatment Market

    Figure 3 Segmentation Market Dynamics for Global Traumatic Brain Injury Treatment Market

    Figure 4 Global Traumatic Brain Injury Treatment Market Share, by Treatment , 2020

    Figure 5 Global Traumatic Brain Injury Treatment Market Share, by End-User, 2020

    Figure 6 Global Traumatic Brain Injury Treatment Market Share, by Region, 2020

    Figure 7 North America: Traumatic Brain Injury Treatment Market Share, by Country, 2020

    Figure 8 Europe: Traumatic Brain Injury Treatment Market Share, by Country, 2020

    Figure 9 Asia-Pacific: Traumatic Brain Injury Treatment Market Share, by Country, 2020

    Figure 10 Middle East & Africa: Traumatic Brain Injury Treatment Market Share, by Country, 2020

    Figure 11 Global Traumatic Brain Injury Treatment Market : Company Share Analysis, 2020 (%)

    Figure 12 Zimmer Biomet: Key Financials

    Figure 13 Zimmer Biomet: Segmental Revenue

    Figure 14 Zimmer Biomet: Geographical Revenue

    Figure 15 Neuren Pharmaceuticals Ltd: Key Financials

    Figure 16 Neuren Pharmaceuticals Ltd: Segmental Revenue

    Figure 17 Neuren Pharmaceuticals Ltd: Geographical Revenue

    Figure 20 Oxygen Biotherapeutics Inc: Key Financials

    Figure 19 Oxygen Biotherapeutics Inc: Segmental Revenue

    Figure 20 Oxygen Biotherapeutics Inc: Geographical Revenue

    Figure 21 TEVA Pharmaceutical Industries Ltd : Key Financials

    Figure 22 TEVA Pharmaceutical Industries Ltd: Segmental Revenue

    Figure 23 TEVA Pharmaceutical Industries Ltd : Geographical Revenue

    Figure 24 Ischemic: Key Financials

    Figure 25 Ischemic: Segmental Revenue

    Figure 26 Ischemic. Geographical Revenue

    Figure 27 Grace Laboratories LLC: Key Financials

    Figure 28 Grace Laboratories LLC: Segmental Revenue

    Figure 29 Grace Laboratories LLC: Geographical Revenue

    Figure 30 Cognosci: Key Financials

    Figure 31 Cognosci: Segmental Revenue

    Figure 32 Cognosci: Geographical Revenue

    Figure 33 Medicortex: Key Financials

    Figure 34 Medicortex: Segmental Revenue

    Figure 35 Medicortex: Geographical Revenue

    Figure 36 Amarantus BioScience Holdings: Key Financials

    Figure 37 Amarantus BioScience Holdings: Segmental Revenue

    Figure 38 Amarantus BioScience Holdings: Geographical Revenue

    Figure 39 Aldagen: Key Financials

    Figure 40 Aldagen: Segmental Revenue

    Figure 41 Aldagen: Geographical Revenue

    Figure 42 NeuroScience Pharmaceuticals : Key Financials

    Figure 43 NeuroScience Pharmaceuticals : Segmental Revenue

    Figure 44 NeuroScience Pharmaceuticals : Geographical Revenue

    Figure 45 Targacept: Key Financials

    Figure 46 Targacept: Segmental Revenue

    Figure 47 Targacept: Geographical Revenue

    Figure 48 BioDirection, Inc: Key Financials

    Figure 49 BioDirection, Inc: Segmental Revenue

    Figure 50 BioDirection, Inc: Geographical Revenue

    Figure 51 QuesGen Systems, Inc: Key Financials

    Figure 52 QuesGen Systems, Inc: Segmental Revenue

    Figure 53 QuesGen Systems, Inc: Geographical Revenue

    Figure 54 BrainScope Company, Inc, Inc: Key Financials

    Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue

    Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue

    Figure 57 Neural Analytics, Inc, Inc: Key Financials

    Figure 58 Neural Analytics, Inc, Inc: Segmental Revenue

    Figure 59 Neural Analytics, Inc, Inc: Geographical Revenue

    Figure 60 Oculogica, Inc: Key Financials

    Figure 61 Oculogica, Inc: Segmental Revenue

    Figure 62 Oculogica, Inc: Geographical Revenue

    Figure 63 BrainScope Company, Inc: Key Financials

    Figure 64 BrainScope Company, Inc: Segmental Revenue

    Figure 65 BrainScope Company, Inc: Geographical Revenue

    Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials

    Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue

    Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue

    Figure 69 Stemedica Cell Technologies Inc: Key Financials

    Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue

    Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue

    Figure 72 Banayan Biomarkers Inc: Key Financials

    Figure 73 Banayan Biomarkers Inc: Segmental Revenue

    Figure 74 Banayan Biomarkers Inc: Geographical Revenue

    Figure 75 Vasopharm GmbH: Key Financials

    Figure 76 Vasopharm GmbH: Segmental Revenue

    Figure 77 Vasopharm GmbH: Geographical Revenue